^
    Back
    Association details:
    Biomarker:MS4A1 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    398P Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study

    Published date:
    11/01/2020
    Excerpt:
    We screened 2926 patients with NSCLC for MET exon 14 skipping mutation. Among them, 14 patients received crizotinib treatment... Interestingly, we also observed NUP93, MS4A1 and ELAC2 mutations in MET acquired point mutation-negative patients, which were restricted to crizotinib resistance.
    DOI:
    10.1016/j.annonc.2020.10.392